Monday, December 19, 2016 / Categories: ChiLDReN, Plain Language Summary Using liver biopsies to characterize biliary atresia and predict outcomes: New results from the Childhood Liver Disease Research Network Biliary atresia is a rare disease of the liver and bile ducts that occurs in infants. It is a type of cholestatic disorder, an umbrella term for any condition in which the flow of bile from the liver stops or slows. A liver biopsy is a key step in distinguishing biliary atresia from other cholestatic disorders. However, the interpretation of liver biopsies in infantile cholestasis is challenging as the histologic features of many of the disorders causing infantile cholestasis overlap, are dynamic, and vary with age. Previous studies of the histologic features which characterize biliary atresia and their correlation with outcomes have been limited, mostly based in single institutions with interpretation by a limited number of pathologists. The Childhood Liver Disease Research Network (ChiLDReN), supported by the National Institutes of Diabetes and Digestive Kidney Diseases (NIDDK), provided the opportunity to evaluate liver biopsies from a large number of jaundiced infants from multiple institutions enrolled in a prospective clinical database. Using data from 227 needle biopsies, researchers identified five independent histologic predictors of a diagnosis of biliary atresia: bile plugs in ducts/ductules, portal stromal edema, no bile duct paucity, absent to rare giant cell transformation, and absent to rare extramedullary hematopoiesis. “This study shows that there is greater variability in the histologic features of biliary atresia in liver biopsies than previously emphasized, which can be problematic for the pathologist,” said lead author Dr. Pierre Russo. “Nonetheless, a number of histologic features, some of which have not been previously well described, together have a high concordance rate with the diagnosis of biliary atresia.” The authors also investigated whether any histologic features in the livers of biliary atresia patients could predict clinical outcomes after a hepatoportoenterostomy (HPE), the primary treatment once a diagnosis of biliary atresia is established. An HPE results in successful bile drainage in half the patients with biliary atresia, but even with successful drainage, most patients will ultimately require liver transplantation. They found that although no histologic features predicted successful bile drainage at six months post-HPE, higher stages of portal fibrosis, ductal plate malformation, bile duct injury, increased INR, and older age at HPE were associated with increased risk of transplantation. CITATION:Russo P, Magee JC, Anders RA, Bove KE, Chung C, Cummings OW, Finegold MJ, Finn LS, Kim GE, Lovell MA, Magid MS, Melin-Aldana H, Ranganathan S, Shehata BM, Wang LL, White FV, Chen Z, Spino C; Childhood Liver Disease Research Network (ChiLDReN). Key Histopathologic Features of Liver Biopsies That Distinguish Biliary Atresia From Other Causes of Infantile Cholestasis and Their Correlation With Outcome: A Multicenter Study. Am J Surg Pathol. 2016;40(12):1601–1615.PubMed:www.ncbi.nlm.nih.gov/pubmed/27776008 Previous Article More efforts needed to reduce financial burdens for living liver donors Next Article Outcomes for hemodialysis patients with hepatitis C infection Print
Arbor Research Awarded a $1.5M Contract to Support AHRQ in Developing their Patient-Centered Outcomes Research Trust Fund (PCORTF) Strategic Plan Thursday, December 8, 2022
Arbor Research Collaborative for Health Awarded $1.2 Million Contract from CDC to Help Nursing Homes Use Electronic Health Records to Report Healthcare Acquired Infections Thursday, October 20, 2022
Arbor Research Collaborative for Health to Serve on Team Evaluating the End-Stage Renal Disease Treatment Choices Model and the Kidney Care Choices Model Friday, September 16, 2022
Arbor Research Collaborative for Health Announces Partnership with Altarum to Support and Evaluate the National Hypertension Control Initiative Tuesday, April 26, 2022
Arbor Research Collaborative for Health Announces Hire of Chauncey Lynch, BS, as Vice President of Finance & Chief Financial Officer Monday, March 28, 2022
PDOPPS: International Icodextrin Use and Association with Peritoneal Membrane Function, Fluid Removal, Patient and Technique Survival Friday, March 18, 2022
Arbor Research Collaborative for Health Announces Hire of Shanthy Edward, M.A., Psy.D. as Vice President of Strategic Growth & Chief Growth Officer Monday, March 7, 2022
Arbor Research Collaborative for Health Appoints Chris Spera, PhD as New President & CEO Friday, November 19, 2021
Launch of the US DOPPS Practice Monitor - Peritoneal Dialysis (DPM-PD), tracking the latest practice trends for patients receiving PD Wednesday, August 25, 2021